(1997). Activation mechanisms of matrix metalloproteinases.
(1999). Active matrix metalloproteinases are present in cartilage during immune complex-mediated arthritis: a pivotal role for Stromelysin-1 in cartilage destruction.
(1992). AJP: The role of the C-terminal domain in collagenase and stromelysin specificity.
(1999). Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis
(1997). Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP-8) to stability and collagenolytic activity by alanine scanning mutagenesis. FEBS Lett
(1994). Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B.
(1997). AR: Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage.
(2001). AR: Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum
(1995). Binding of gelatinases A and B to type-I collagen and other matrix components.
(1989). Brinckerhoff CE: Cloning of the genes for human stromelysin and stromelysin 2: differential expression in rheumatoid synovial fibroblasts. Biochemistry
(1998). Buttle DJ: Stromelysin 1, neutrophil collagenase, and collagenase 3 do not play major roles in a model of chondrocyte mediated cartilage breakdown. J Clin Pathol Mol Pathol
(2001). Cawston T: The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders. Drugs Aging
(2000). Cawston TE: Matrix metalloproteinase inhibitors in the treatment of arthritis. Curr Opin Anti-Inflamm Immunomodulat Invest Drugs
(2001). CE: Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1beta. Arthritis Res
(2001). Characterization of the role of the ‘MT-loop’: an eight-amino acid insertion specific to progelatinase A (MMP2) activating
(1977). Collagenase and its natural inhibitors in relation to the rheumatoid joint. Connect Tissue Res
(1997). Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ — In vitro mimicking effect by transforming growth factor? Arthritis Rheum
(1998). Comparative immunolocalization studies of collagenase 1 and collagenase 3 production in the rheumatoid lesion, and by human chondrocytes and synoviocytes in vitro.
(1998). d’Ortho M-P, Murphy G: The TIMP2 membrane type 1 metalloproteinase ‘receptor’ regulates the concentration and efficient activation of progelatinase A.
(1999). Design and synthetic considerations of matrix metalloproteinase inhibitors.
(1995). DL: Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients Available online http://arthritis-research.com/content/4/S3/S039S48 with osteo- and rheumatoid arthritis. Ann Rheum Dis
(1994). Docherty AJP: Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant.
(1976). DR: Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells.
(1998). DS: Matrix metalloproteinase inhibitors in arthritis.
Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics. Arthritis Res 2002, 4(suppl 3):S51-S61. [general reference]
(1991). Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. Arthritis Rheum
(1993). G: The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry
(2001). G: The role of exon 5 in fibroblast collagenase (MMP-1) substrate specificity and inhibitor selectivity.
(1993). GI: Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1.
(1999). Goldberg VM: Future directions for research and treatment of osteoarthritis. Front Biosci
(1999). H: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis and connective tissue disease due to inadequate collagen turnover. PubMed Cell
(2001). Henney AM: Detecting polymorphisms in MMP genes.
(1993). Hutchinson NI: Differential in vivo expression of collagenase messenger RNA in synovium and cartilage. Arthritis Rheum
(1995). Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes.
(1999). Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis? Drugs
(1993). JA: Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain.
(2001). JD: Inhibition of tumor necrosis factor-α α (TNF-α α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α α-converting enzyme and matrix metalloproteinases. J Pharm Exp Ther
(1998). Konttinen YT: Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int
(1992). Lark MW: Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum
(1997). López-Otín C: Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum
(2001). Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum
(1997). Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature
(1997). Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases.
(1998). Membrane-type matrix metalloproteinases and cell surface-associated activation cascades for matrix metalloproteinases. In Matrix Metalloproteinases. Edited by Parks WC, Mecham RP.
(2001). MW: Identification and initial characterisation of 5000 expressed sequence tags (ESTs) each from adult normal and osteoarthritic cartilage cDNA libraries. Ostoearthritis Cartilage
(1993). MW: Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum
(1996). Nagataki S: TNF-alpha-mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts. Immunology
(1998). New collagenolytic enzymes cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: Destruction from above. Matrix Biol
(2000). Overall CM: Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science
(1995). Proteolytic remodeling of extracellular matrix.
(2001). Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain.
(2000). Structural basis of the endoproteinaseprotein inhibitor interaction.
(1996). The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation — Regulation by TIMP-2 and TIMP-3.
(1997). Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Expr
(1997). Tschesche H, Salo T: Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline.
(2001). Tyrosine 36 plays a critical role in the interaction of the AB loop of tissue inhibitor of metalloproteinases-2 with matrix metalloproteinase-14.
(1999). van den Berg W: Cleavage of aggrecan at the ASN341-PHE342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis. A pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arthritis Rheum
(1999). Woessner JF: Matrix metalloproteinases.
(2000). Z: Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev